Since the coronavirus pandemic began, the Internet Protocol team has repeatedly covered news related to Dr. Vladimir Zelenko’s treatment protocol and how it affected and helped people who had the COVID-19 disease. We contacted Dr. Zelenko multiple times to hear about updates in treating patients using his experimental protocol.
The Internet Protocol
Dr. Zelenko is a 46-old doctor who has been working in the United States for the past 16 years. Over the past few months of the global pandemic, he has become known for claiming to have developed a drug regimen for treating coronavirus. According to Vladimir Zelenko’s information, he managed to cure hundreds of people using his COVID-19 treatment plan.
And although many refuted the treatment according to Zelenko’s technique and criticized it, calling it inefficient and saying it caused side effects that affected patients’ well-being, there still were supporters of his ideas.
Also, recently, other studies have confirmed the positive results of the doctor’s treatment protocol. For instance, the NYU study concludes that using the triplet of drugs suggested by Dr. Zelenko reduced the mortality rate of COVID-19 patients and their need for ventilators to support their vital activities.
NYU Study concludes using Hydroxychloroquine + Zinc + Azithromycin reduced death, hospice transfers, and the need for ventilation. Use of the drugs also increases the frequency in which patients were discharged home https://t.co/Q4DFsXXwGv pic.twitter.com/YLncTvfkWC
— Dr. Zev Zelenko (@zev_dr) July 2, 2020
Our team has received a version of a study on the treatment protocol that is now getting ready to be published in medical journals. We had no intention to publish it ahead of time before it was officially out.
However, CNN has published an article about the study that finds that hydroxychloroquine helped COVID-19 patients survive better. According to CNN, a team at Henry Ford Health System in Southeast Michigan conducted a study on 2,541 hospitalized coronavirus patients and discovered that those who were given hydroxychloroquine were more likely to survive.
Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, stated that 26% of those who were not given hydroxychloroquine died, compared to 13% of those who did take the medicine.
These results are quite surprising as other studies on hydroxychloroquine, a drug initially developed to treat malaria, found it inefficient in treating COVID-19 and stated it caused cardiac side effects.
The Internet Protocol
Taking into account an increasing number stating that hydroxychloroquine might help coronavirus patients survive better, now seems like the right time to share the study we were able to obtain in full as there is no point in being silent about it.
You can read the full study and its results here.
The study’s main objective is to describe outcomes of patients with coronavirus disease in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (the triple therapy) dependent on risk stratification. The study involved 141 COVID-19 patients with the laboratory-confirmed severe acute respiratory syndrome in 2020.
The conclusion of the study is as follows:
Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.
